Recursion Pharmaceuticals Files 8-K

Ticker: RXRX · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1601830

Recursion Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRecursion Pharmaceuticals, Inc. (RXRX)
Form Type8-K
Filed DateSep 3, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.00001, $58.77 million, $6.88 million
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory

Related Tickers: RXRX

TL;DR

RXRX filed an 8-K on Sept 3rd covering various disclosures and financial updates.

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on September 3, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is based in Salt Lake City, UT.

Why It Matters

This 8-K filing provides important updates and disclosures from Recursion Pharmaceuticals, Inc. to investors and the public regarding company events and financial information.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain specific material events that would inherently increase risk.

Key Players & Entities

  • RECURSION PHARMACEUTICALS, INC. (company) — Registrant
  • September 3, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 46-4099738 (id) — I.R.S. Employer Identification No.
  • 41 S Rio Grande Street (address) — Principal executive offices
  • Salt Lake City, UT 84101 (address) — Principal executive offices
  • 001-40323 (id) — Commission File Number

FAQ

What is the primary purpose of this Form 8-K filing?

This Form 8-K filing serves as a current report by Recursion Pharmaceuticals, Inc. to disclose information regarding Regulation FD disclosures, other events, and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on September 3, 2024.

In which state is Recursion Pharmaceuticals, Inc. incorporated?

Recursion Pharmaceuticals, Inc. is incorporated in Delaware.

What is the principal executive office address for Recursion Pharmaceuticals, Inc.?

The principal executive office address is 41 S Rio Grande Street, Salt Lake City, UT 84101.

What is the Commission File Number for Recursion Pharmaceuticals, Inc.?

The Commission File Number for Recursion Pharmaceuticals, Inc. is 001-40323.

Filing Stats: 4,382 words · 18 min read · ~15 pages · Grade level 18.8 · Accepted 2024-09-03 08:01:53

Key Financial Figures

  • $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
  • $58.77 million — ntia a termination fee of approximately $58.77 million or reimburse Exscientia for certain fee
  • $6.88 million — sion a termination fee of approximately $6.88 million; Recursion and Exscientia are subject

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion" or the "Company") released an updated investor presentation. The investor presentation will be used from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1. The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. SYCAMORE Trial Top-Line Results On September 3, 2024, the Company issued a press release announcing top-line results of its SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic cerebral cavernous malformation patients. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein. Certain Financial Information Relating to the Proposed Transaction with Exscientia As previously disclosed in the Current Report on Form 8-K filed on August 8, 2024 (the "Original Form 8-K"), the Company, entered into a transaction agreement dated August 8, 2024 (the "Transaction Agreement") with Exscientia plc ("Exscientia"). The Transaction Agreement provides that, subject to the terms and conditions set forth therein, including the requisite approval of each of the Company's stockholders and Exscientia's shareholders, the Company will acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme of Arrangement" and such transaction, the "Transaction"). In connection with the Transaction Agreement, the proposed Transaction, and the related transactions described in this Current Report on Form 8-K and the Original Form 8-K, which description is hereby incorporated by reference herein , the Company is providing the following information: The Company is filing the following financial information related to Exscientia and the proposed Transaction: The audited consolidated statement of financial position of Exscientia as of and for the years ended December 31, 2023, and December 31, 2022, and the related consolidated statement of loss and other comprehensive (loss)/income, of changes in equity and of cash flows for each of the three years in the period ended December 31, 2023 are attached as Exhibit 99.3 her

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.